Aberrant expression of anaplastic lymphoma kinase (ALK) is the oncogenic driver of 3-7% of non-small cell lung cancer (NSCLC) cases. Six ATP-competitive tyrosine kinase inhibitors (TKIs) of ALK have been approved by the FDA to treat patients with ALK-positive NSCLC, but mutations conferring drug resistance often occur in the ATP-binding pocket of ALK signifying a need for alternative modalities to inhibit ALK function. Here we report that ALK-driven tumor growth can be suppressed by novel molecular glue cereblon E3 ligase modulatory drugs (CELMoDs) that trigger ubiquitylation and subsequent proteasomal degradation of ALK. A cryo-EM structure of the ALK-CELMoD-cereblon ternary complex revealed that ALK interacts with cereblon and drug through a site distal to its ATP-binding pocket and features a surprising degron structure distinct from the canonical G-loop degron established for other cereblon neosubstrates. Subsequent lead optimization identified a series of ALK CELMoDs with improved brain penetration. Our in vitro and in vivo studies support the hypothesis that a brain penetrant ALK CELMoD would be an effective therapy for ALK-positive NSCLC with similar or better efficacy and safety profile compared to TKIs. Furthermore, combination treatment with TKIs might enhance ALK CELMoD efficacy due to distinct binding sites and mechanisms of action. Finally, the novel degron suggests that the degradome of CELMoDs goes beyond G-loop-containing proteins, thus emphasizing the importance and potential of this modality to target a wide spectrum of previously un-druggable proteins in human diseases. Zheng Wang, Massimo Ammirante, Martina Malatesta, Alex Cortez, Young Chen, Jinyi Zhu, Dahlia Weiss, Vijaya Lakshmi Dommeti, Geraldine Hernandez, Joshua M. Baughman, Adwait Sathe, Matthew Groza, Maria Donoso, Roxxana Beltran, Regina Paramitha, Ryan Davison, Atefeh Garzan, Barbra Pagarigan, Michelle Slade, Jacobo Fuentes, Jennifer Buenviaje, Shan Yu, Xinde Zheng, Andres H de la Peña, Mariko Riley, Gabe Mintier, Surendra Nayak, Shuichan Xu, Rama Narla, Ellen Filvaroff, Deborah Mortensen, Lihong Shi, Celia Fontanillo Fontanillo, Christoph Zapf, Neil Bence, Mark Rolfe. Brain-penetrant molecular glue degraders targeting ALK via a novel degron: a potential therapeutic approach for ALK-positive NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6378.

The androgen receptor (AR) is a key driver of the cellular processes that contribute to the pathology of prostate cancers at most stages, and drugs that inhibit the activity of this receptor or which interfere with androgen biosynthesis have become the cornerstone of treatments for prostate cancer. Nevertheless, de novo and acquired resistance remains an impediment to a durable clinical response in patients with metastatic castration-resistant prostate cancer (mCRPC), and overcoming resistance to AR pathway inhibitors (ARPIs) has emerged as a major challenge in the treatment of patients with mCRPC. CC2000199 (also called CC-199) is a heterobifunctional ligand-directed degrader (LDD) that enables CRL4CRBN E3 ligase-dependent ubiquitination and degradation of AR and a close analog of BMS-986365. It is a highly potent and selective AR degrader that induces rapid and deep degradation of both wildtype and mutant forms of the receptor. In addition to AR degradation, CC-199 displays AR-inhibitory activity as a direct receptor antagonist with a potency similar to enzalutamide (ENZ) for wildtype AR. The drug is ∼100-fold more potent than ENZ at inhibiting androgen-stimulated transcription of AR target gene FKBP5, and ∼10- to 40-fold more potent than ENZ at inhibiting AR-dependent proliferation of multiple prostate cancer cell lines in vitro. In animal models of advanced prostate cancer, CC-199 demonstrates on-target activity, inducing deep AR degradation, suppressing AR signaling, and inhibiting tumor growth. Indeed, significant tumor volume reductions were achieved by CC-199 in validated models of advanced CRPC and therapy resistant patient-derived xenografts, including those with acquired resistance to ENZ. Collectively, our preclinical data suggest that the AR degrader CC-199 is superior to standard-of-care AR antagonists, such as ENZ, in disease-relevant animal models and ENZ-resistant mCRPC that remain dependent on AR. Surendra Nayak, Massimo Ammirante, Emily Rychak, Debbie Liao, John D. Norris, Suzanne E. Wardell, Shailaja Kasibhatla, Veronique Plantevin-Krenitsky, Evan Horn, Joseph R. Piccotti, Stephen Norris, Raju Kandimalla, Joseph Meiring, Samantha Reiss, Joshua M. Baughman, Marwa Khater, Deborah S. Mortensen, Brian Cathers, Neil Bence, Daniel W. Pierce, Joshua D. Hansen, Lawrence G. Hamann, Donald P. McDonnell, Rama K. Narla, Mark Rolfe, Shuichan Xu. CC2000199, a potent and selective androgen receptor ligand-directed degrader (AR LDD) with a dual mechanism of action, exhibits anti-tumor activity in multiple enzalutamide-resistant preclinical models for metastatic castration-resistant prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1647.

Most prostate cancers express the androgen receptor (AR), and tumor growth and progression are facilitated by exceptionally low levels of systemic or intratumorally produced androgens. Thus, absolute inhibition of the androgen signaling axis remains the goal of current therapeutic approaches to treat prostate cancer (PCa). Paradoxically, high dose androgens also exhibit considerable efficacy as a treatment modality in patients with late-stage metastatic PCa. Here we show that low levels of androgens, functioning through an AR monomer, facilitate a non-genomic activation of the mTOR signaling pathway to drive proliferation. Conversely, high dose androgens facilitate the formation of AR dimers/oligomers to suppress c-MYC expression, inhibit proliferation and drive a transcriptional program associated with a differentiated phenotype. These findings highlight the inherent liabilities in current approaches used to inhibit AR action in PCa and are instructive as to strategies that can be used to develop new therapeutics for this disease and other androgenopathies.

Abstract The androgen receptor (AR) is a key driver of the cellular processes that contribute to the pathology of prostate cancers at most stages, and drugs that inhibit the activity of this receptor or interfere with androgen biosynthesis have become the cornerstone of treatments for prostate cancer. While both types of therapy have had a significant positive impact on disease progression and overall survival, de novo and acquired resistance remains an impediment to a durable clinical response in patients with metastatic castration-resistant prostate cancer (mCRPC). The mechanisms underlying drug resistance are complex and multifactorial, being attributable to AR overexpression, point mutations in the receptor that alter drug pharmacology, and to the upregulation of receptor-associated coregulators, which render AR less dependent on an activating ligand. Regardless, absolute inhibition of AR signaling remains the objective of contemporary approaches to treat prostate cancer. Recently, there has been specific interest in the development of approaches to eliminate AR proteins using drugs that enable targeted degradation of AR in cancer cells.This puts in context the significance of our discovery of BMS-986365 (also known as CC-94676), a heterobifunctional ligand-directed degrader (LDD) that enables the CRL4CRBN E3 ligase-dependent ubiquitination and degradation of AR (DC50 10 to 40 nM, Ymin 7 to 19%). BMS-986365 is a highly potent and selective AR degrader that induces rapid and deep degradation of both wildtype and mutant forms of the receptor residing in either the cytoplasmic or nuclear compartments of the cell. The drug is ~100-fold more potent than enzalutamide (ENZ) at inhibiting androgen-stimulated transcription of AR target genes, and 10 to 120-fold more potent than ENZ at inhibiting AR-dependent proliferation of multiple prostate cancer cell lines in vitro. In animal models of advanced prostate cancer, BMS-986365 demonstrates on-target activity, degrading AR, suppressing AR signaling, and inhibiting tumor growth. Indeed, tumor volume reductions of 63-92% were achieved by BMS-986365 in validated models of advanced CRPC and therapy resistant patient-derived xenografts, including those with acquired resistance to ENZ. Collectively our preclinical data suggest that the AR degrader BMS-986365 is superior to standard-of-care AR antagonists, such as ENZ, in both preclinical and disease-relevant animal models, and support its clinical development for treatment of prostate cancer. BMS-986365 has advanced into clinical studies where it has demonstrated encouraging clinical activity in patients with mCRPC. Citation Format: Shuichan Xu, Surendra Nayak, John D. Norris, Massimo Ammirante, Emyly Rychak, Suzanne E. Wardell, Toshiya Tsuji, Ken Liu, Joseph Meiring, Joseph R. Piccotti, Deepak Dalvie, Debbie Liao, Raju Kandimalla, Nadia Guerrero, Lisa Sapinoso, Jennifer G. Baker, Yeeun Bae, Joshua Baughman, Brandon Toyama, Celia Fontanillo Fontanillo, Stephen Norris, Evan J. Horn, Veronique Plantevin-Krenitsky, Deborah Mortensen, Brian Cathers, Marie Hong Nguyen, Joshua D. Hensen, Lawrence G. Hamann, Donald P. McDonnell, Rama Krishna Narla, Mark Rolfe. Discovery of BMS-986365, a ligand-directed androgen receptor degrader (AR LDD) with a dual mechanism-of-action and best-in-class potential, for the treatment of advanced prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr ND02.

BACKGROUND:Hydrated strontium perchlorate [Sr(ClO4)2.3H2O] acts as a very strong oxidizing and dehydrating agent. Until now, it could not be reported as a catalyst in dehydration mechanism-based organic synthetic reactions. Therefore, it is important to find whether it could be an effective catalyst for one-pot multicomponent reactions (MCRs).OBJECTIVE:The main objective of the present work is the development of a novel process for the synthesis of 1,4-dihydropyrimidinones through the one-pot multicomponent strategy using hydrated Sr(ClO4)2 as a catalyst. Furthermore, it includes process optimization, stereoselectivity, and spectroscopic characterization of the synthesized compounds.METHODS:Conventional and microwave-supported synthesis of 1,4-dihydropyrimidinones using 20 mol % of hydrated Sr(ClO4)2 catalyst via the one-pot solvent-free reaction was discovered as a new catalytic MCR methodology. The box-Behnken design approach and advanced analytical techniques were used for process optimization and reaction analysis.RESULTS:The results confirmed that hydrated Sr(ClO4)2; works as an efficient catalyst for one-pot multicomponent organic synthesis under both conventional and microwave heating. It is an effective catalyst for laboratory synthesis of 1,4-dihydropyrimidinones stereoselectively with moderate to excellent yield without any undesirable effect. Microwave heating provided the desired product within 1-4 minutes. Moreover, this method provides easy isolation of the pure products simply by recrystallization, and without the use of a chromatographic purification method.CONCLUSION:The simplicity and neutrality of reaction conditions, easy post-reaction workup, higher satisfactory to excellent yield, effectiveness, the diversity of substrates, etc. render the hydrated Sr(ClO4)2 catalyst-based protocol for the stereoselective synthesis of 1,4-dihydropyrimidinones as a highly efficient method. Furthermore, it has been found to be safe un-der laboratory reaction conditions and no undesirable issues have been faced during the process.

Modulating the chemical composition of cereblon (CRBN) binders is a critical step in the optimization process of protein degraders that seek to hijack the function of this E3 ligase. Small structural changes can have profound impacts on the overall profile of these compounds, including depth of on-target degradation, neosubstrate degradation selectivity, as well as other drug-like properties. Herein, we report the design and synthesis of a series of novel CRBN binding moieties. These CRBN binders were evaluated for CRBN binding and degradation of common neosubstrates Aiolos and GSPT1. A selection of these binders was employed for an exploratory matrix of heterobifunctional molecules, targeting CRBN-mediated degradation of the androgen receptor.

BACKGROUND:Epidemiological studies have suggested that a regular intake of flavonoids is beneficial for cellular homeostasis and in the prevention of the transformation of normal cells into cancerous cells. Because of their multiple biological targets, flavonoids have been studied and investigated as phytoconstituents with potential anticancer properties. Flavonoids interfere in the development of cancerous cells by inhibition of topoisomerases, protein kinases, angiogenesis, induction of apoptosis, cell cycle arrest, modulation of multidrug resistance, and improvement in anti-oxidative activities. The current review summarizes the anticancer properties of flavonoids along with the key structural features and their mechanisms. The present study provides a detailed analysis of anticancer activities with previously published data on different flavonoids. The review highlighted the structural aspects and mechanism of action of flavonoids with their potential target sites. Flavonoids induce anticancer activity by protein kinases inhibition, P-gp modulation, antiangiogenesis, topoisomerases inhibition, etc. Open ring C, the double bond between C2-C3, the oxo group at C4, and the position of ring B are crucial determinants for their anticancer activity. Flavonoids act by multiple mechanisms but further studies on target selectivity and specificity of flavonoids are necessary to establish them as anticancer therapeutics. The presence of a C2-C3 double bond and oxo group at C4 (also known as an enone moiety) or -OH in the neighbour of a double bond that can transform easily into an enone are common features present in flavonoids. Thus, it can be concluded that enone moiety or its precursor groups are mainly responsible for the anticancer activities of flavonoids via different mechanisms of action.

A number of catalytic synthetic reactions have been reported which play the important role in stereochemistry of compounds. The key to the success of this protocol was the generation of stereogenic centers in 1, 4-Dihydropyrimidinones (DHPMs) and the influence of catalysts on their configuration. Waste brick dust was found to be an effective catalyst, generating chiral DHPMs derivatives using aryl aldehyde, urea, and ethyl acetoacetate. This work mainly focuses on the stereochemistry of brick-dust catalyzed DHPMs derivatives. Discovery of brick dust catalyst associated with several benefits such as rapid clean reaction, simple, and ease work-up.

Microwave-supported strontium percholrate Sr(ClO 4 ) 2 catalyzed synthesis of aryl-14 H -dibenzo[ a,j ]xanthene derivatives ( 3a-k ) via one-pot three component condensation of substituted or unsubstituted aryl aldehyde with β-naphthol under solvent free-condition was discovered as a new methodology. Synthesized xanthene derivatives were analyzed on the basis of TLC, melting points, FT-IR, 1 HNMR, and MS data. The result confirmed that Sr(ClO 4 ) 2 acts as strong dehydrating catalyst to enhance the rate of reaction. Typically, the approach involves mixing of reactants in presence of catalyst (20% w/w) followed by microwave heating for 1-6 minutes to obtain the desired products. The key features of present method include the commercial availability of catalyst, solvent-free conditions, one-pot methodology, short reaction time, higher yield, easy separation of catalyst, simple workup, and ease in product purification

The present study was conducted to understand the effect of vitamin C and mineral enriched diet on growth, survival and mineral accumulation in Labeo rohita fry. The study was conducted for a period of 60 days and it was found that the growth and survival rate increased when local ingredients were fortified with commercially available and commonly used vitamin-mineral mixture, vitamin C and selected mineral elements (Zn, Cu and Mn). The best survival rate (76%) was recorded when feed was supplemented with all the three components (vitamin-mineral mixture, vitamin C and mineral supplement), followed by vitamin-mineral mixture + vitamin C (75.3%) and vitamin-mineral mixture. The Zn, Cu and Mn fortification in the diet also reflected higher deposition of these three minerals in the whole body as well as 38.4% reduction in the cost of production and 152.6% higher revenue generation compared to commercial feed (control). Keywords: Copper, Labeo rohita, Manganese, Vitamin C, Zinc

The alpha (α)-amylase is a calcium metalloenzyme that aids digestion by breaking down polysaccharide molecules into smaller ones such as glucose and maltose. In addition, the enzyme causes postprandial hyperglycaemia and blood glucose levels to rise. α-Amylase is a well-known therapeutic target for the treatment and maintenance of postprandial blood glucose elevations. Various enzymatic inhibitors, such as acarbose, miglitol and voglibose, have been found to be effective in targeting this enzyme, prompting researchers to express an interest in developing potent alpha-amylase inhibitor molecules. The review mainly focused on designing different derivatives of drug molecules such as benzofuran hydrazone, indole hydrazone, spiroindolone, benzotriazoles, 1,3-diaryl-3-(arylamino) propan-1-one, oxadiazole and flavonoids along with their target-receptor interactions, IC50 values and other biological activities.

Background: COVID-19 has become a pandemic with higher morbidity and mortality rates after its start from Wuhan city of China. The infection by RNA virus, also known as SARS-CoV-2 or 2019-nCoV, from the beta class of coronaviruses, has been found to be responsible for COVID-19. Structural analysis and evidences have been indicated that interaction between a segment of receptor binding domain (RBD) from S protein of the virus and human angiotensin-converting enzyme 2 (hACE2) is essential for cellular entry of the virus. Objective: The current review sheds light on structural aspects for the inhibition of RBD-hACE2 interaction mediated cellular entry of SARS-CoV-2. Methods: The present study provides a critical review of recently published information on RBD-hACE2 interaction and its inhibitors to control SARS-CoV-2 infection. The review highlighted the structural aspects of the interaction between RBD-hACE2 and involved amino acid residues. Results: Recently, several studies are being conducted for the inhibition of the SARS-CoV-2 attachment and entry to the human cellular system. One of the important targets for viral invasion is its binding with cell surface receptor, hACE2, through RBD on S-protein. Mimicking of three residues on ACE2 (Lys31, Glu35 and Lys353 on B chain) provided a hot target directed strategy for the inhibition of early attachment of the virus to the cell. Early screening of peptidic or non-peptidic molecules for the inhibition of RBD-hACE2 interaction has raised the hope for potential therapeutics against COVID-19. The higher affinity of molecules toward RBD than ACE2 is an important factor for selectivity and minimization of ACE2 related adverse events on the cardiovascular system, brain, kidney, and foetus development during pregnancy. Conclusion: Inhibition of RBD-hACE2 interaction by different molecular scaffolds can be used as a preferred strategy for control of SARS-CoV-2 infection. Recently, published reports pointed out Lys31, Glu35 and Lys353 on the B chain of ACE2 as crucial residues for mimicking and design of novel molecules as inhibitors SARS-CoV-2 attachment to human cells. Moreover, some recently identified RBD-hACE2 interaction inhibitors have also been described with their protein binding pattern and potencies (IC50 values), which will help for further improvement in the selectivity.

Background: Among the millions of people around the world, the most prevalent metabolic disorder is diabetes mellitus. Due to the drawbacks which are associated with commercially available antidiabetic agents, new therapeutic approaches are needed to be considered. Alpha-amylase is a membrane-bound enzyme which is responsible for the breakdown of polysaccharides such as starch to monosaccharides which can be absorbed. Methods: We searched the scientific database using alpha-amylase, diabetes, antidiabetic agents as the keywords. Here in, only peer-reviewed research articles were collected which were useful to our current work. Results: To overcome the research gap, the alpha-amylase enzyme is regarded as a good target for antidiabetic agents to design the drug and provide an alternate approach for the treatment of type 2 diabetes mellitus. Basically, alpha-amylase inhibitors are classified into two groups: proteinaceous inhibitors, and non-proteinaceous inhibitors. Recently, non-proteinaceous inhibitors are being explored which includes chalcones, flavones, benzothiazoles, etc. as the potential antidiabetic agents. Conclusion: Herein, we discuss various potential antidiabetic agents which are strategically targeted alpha-amylase enzyme. These are having lesser side effects as compared to other antidiabetic agents, and are proposed to prevent the digestion and absorption of glucose leading to a decrease in the blood glucose level.

: Among the non-communicable diseases (NCDs) cancer is a major global health burden with low survival rate. According to WHO’s Globocan-2018 report, the developing countries of Africa and Asia are contributing more to 7 million new cases and 6 million figures of death due to non-availability of targeted and affordable treatment. The selective targeting of biological targets in cancerous cells or tissue is a crucial criterion for successful treatment of cancer. The continuous findings in the area anticancer therapeutic development have been provided variety of potential targets such as receptors, proteins, enzymes, nucleic acids etc. which are present in cancer cells. Here, we provided detail on different biological targets and their biological role in cancer. Additionally, some clinically used as well as novel molecular agent acting on these anticancer targets have been included along with updation. This paper will be helpful in the target specific design and development of novel anticancer therapeutics.

Homoisoflavonoids are important subcategory of flavonoids and present in wide range of plant families. Till date approximately 300 homoisoflavonoids have been identified and evaluated for various biological activities such as anti-cancer, anti-diabetics, antiinfective, anti-inflammatory anti-oxidant etc. Dominating homoisoflavonoids exhibit stereoisomerism thus isolation of a single isomer is tedious process, however, some recent advances has been made in their extraction and isolation. Moreover, the low concentration of homoisoflavonoids in plants appreciated their chemical synthesis by different methods. Homoisoflavonoids have also been explored for their molecular mechanisms which are responsible for biological activities. Here, we reviewed advancement in the isolation, synthesis and biological activities of homoisoflavonoids.

The emergence of drug resistance in infectious microbial strains can be overcome by development of novel drug molecules against unexploited microbial target. The success of Bedaquiline in recent years, as FoF1 ATP synthase inhibitor against XDR and MDR mycobacterium strains, has resulted in further exploration to identify more potent and safe drug molecules against resistant strains. FoF1 ATP synthase is the main energy production enzyme in almost all eukaryotes and prokaryotes. Development of bacterial ATP synthase inhibitors is a safe approach, without causing harm to mammalian cells due to structural difference between bacterial and mammalian ATP synthase target sites. This review emphasizes on providing the structural insights for FoF1 ATP synthase of different prokaryotes and will help in the design of new potent antimicrobial agents with better efficacy. Further, applications of synthetic and natural active antimicrobial ATP synthase inhibitors, reported by different research groups are summarized. Their SAR and mode of actions are also analysed.

Breast cancer is the most common type of malevolent tumour in females, constituting about 30% of all cancers in females worldwide. Incidence rate of disease has increased by 20% since 2008 globally. Moreover, the complexity of disease arises due its variable nature and several types. However, in the past few years, mortality rate of disease has been reduced significantly due to adoption of various treatments like surgery, radiation, chemotherapy etc, and emergence of breast cancer screening. At present, chemotherapy is the most efficient treatment for disease. However, their side effects cause a long term provocation on patient’s health. Thus, there is a need to develop a new treatment strategy that can only target the malignant cells without causing any harm to the adjacent body cells. Nanomedicines are auspicious alternative for treatment of breast cancer. Nanomedicines refer to materials having biomedical applications and have size range below 100 nm. A variety of nanocarriers are available like polymeric nanoparticles, dendrimers, nanotubes, liposomes, etc. Some of the nanocarriers like liposomes (Doxil) and nanoparticles (Abraxane) have been used successfully for breast cancer treatment. These nanomedicines hold immense potential to refine treatment strategies against breast cancer. They can enhance the pharmacodynamics and pharmacokinetics profiles of conventional treatments and may optimize the efficacy of existing drugs. Site specific delivery of anticancer drugs using nanocarriers results in increased therapeutic efficiency of conventional drugs. Nanomedicines based approaches are used to understand the interaction of cancerous cells with their surrounding cells. This review provides insight knowledge about the pathophysiology, current risk factors, types of breast cancers, and targeted drug delivery for breast cancer using nanomedicines approach to conquer the limitations of conventional therapy.

BACKGROUND:Heterocycles containing thiazole, a moiety with sulfur and nitrogen is a core structure which is found in a number of biologically active compounds. The thiazole ring is notable as a component of the certain natural products, such as vitamin B1 (thiamine) and penicillins. Thiazole is also known as wonder nucleus and has uses in different biological fields. A number of new compounds contain heterocycle thiazole moieties, thus it is one of the important areas of research.METHODS:We searched the scientific database using relevant keywords. Among the searched literature only peer-reviewed papers were collected which addresses our questions. The retrieved quality research articles were screened and analyzed critically. The key findings of these studies were included along with their importance.RESULTS:The quality research articles included in this review were selected for the lifethreatening diseases i.e. diabetes, which is one of the serious issues all over the globe with an estimated worldwide prevalence in 2016 of 422 million people, which is expected to rise double to by 2030. Since 1995, there has been an explosion of the introduction of new classes of pharmacological agents having thiazole moieties. However, most of the drugs can cause noncompliance, hypoglycemia, and obesity. Thus, new antidiabetic drugs with thiazole moieties came up with improved compliance and reduced side effects such as pioglitazone (Actos), rosiglitazone (Avandia), netoglitazone, DRF-2189, PHT46, PMT13, DRF-2519. With such a great importance, research in thiazole is part of many academic and industrial laboratories worldwide.CONCLUSION:The present review describes the importance of thiazole nucleus and its derivatives as antidiabetic agents with an emphasis on the past as well as recent developments.